{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:39:21Z","timestamp":1791488361610,"version":"4.3.4"},"reference-count":28,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncoscience"],"published-print":{"date-parts":[[2013,12,12]]},"DOI":"10.18632\/oncoscience.4","type":"journal-article","created":{"date-parts":[[2015,9,27]],"date-time":"2015-09-27T02:03:44Z","timestamp":1443319424000},"page":"14-20","source":"Crossref","is-referenced-by-count":11,"title":["Expression of Cancer\/Testis genes in ductal carcinoma in situ and benign lesions of the breast"],"prefix":"10.18632","volume":"1","author":[{"given":"Otavia L.","family":"Caballero","sequence":"first","affiliation":[{"name":"Ludwig Collaborative Laboratory, Ludwig Institute for Cancer Research, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Shousha","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust & Imperial College, London, Charing Cross Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Ludwig Collaborative Laboratory, Ludwig Institute for Cancer Research, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J. G.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research, New York, NY., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Charles","family":"Coombes","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust & Imperial College, London, Charing Cross Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Munro","family":"Neville","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research, New York, NY., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ. Cancer\/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005; 5(8):615-625. [PubMed]","DOI":"10.1038\/nrc1669"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Caballero OL and Chen YT. Cancer\/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009; 100(11):2014-2021. [PubMed]","DOI":"10.1111\/j.1349-7006.2009.01303.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T, Chen YT, Chua R, Gurung S, Gnjatic S, Jungbluth AA, Caballero OL, Bairoch A, Kiesler E, White SL, Simpson AJ, et al. CTdatabase: a knowledgebase of high-throughput and curated data on cancertestis antigens. Nucleic Acids Res. 2009; 37(Database issue):D816-819. [PubMed] https:\/\/doi.org\/10.1093\/nar\/gkn673.","DOI":"10.1093\/nar\/gkn673"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ, Jungbluth AA, Miller LD, Clouston D, Cebon J, Old LJ, Lakhani SR, Simpson AJ and Neville AM. CT-X antigen expression in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(32):13493-13498.[PubMed] https:\/\/doi.org\/10.1073\/pnas.0906840106.","DOI":"10.1073\/pnas.0906840106"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Curigliano G, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, Neville AM, Nole F, Rotmensz N and Goldhirsch A. Cancer-testis antigen expression in triplenegative breast cancer. Ann Oncol. 2011; 22(1):98-103. [PubMed]","DOI":"10.1093\/annonc\/mdq325"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY. 2004; 6(1):1-6. [PubMed]","DOI":"10.1016\/S1476-5586(04)80047-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, Hoda SA, Simpson AJ, Old LJ, Caballero O and Neville AM. Multiple cancer\/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One. 2011; 6(3):e17876. [PubMed] https:\/\/doi.org\/10.1371\/journal.pone.0017876.","DOI":"10.1371\/journal.pone.0017876"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Bombonati A and Sgroi DC. The molecular pathology of breast cancer progression. J Pathol. 2011; 223(2):307-317. [PubMed] https:\/\/doi.org\/10.1002\/path.2808.","DOI":"10.1002\/path.2808"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, Leone A, Gazzotti F, Gagliardi S, De Cataldis A and Taffurelli M. 259 Patients with DCIS of the breast applying USC\/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat. 2008; 109(3):405-416. [PubMed]","DOI":"10.1007\/s10549-007-9668-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM and Tlsty TD. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010; 102(9):627-637. [PubMed] https:\/\/doi.org\/10.1093\/jnci\/djq101.","DOI":"10.1093\/jnci\/djq101"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Horimoto Y, Tokuda E, Arakawa A, Kosaka T, Saito M and Kasumi F. Significance of HER2 protein examination in ductal carcinoma in situ. J Surg Res. 2011; 167(2):e205210. [PubMed]","DOI":"10.1016\/j.jss.2009.07.030"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N and Old LJ. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer. 2001; 92(6):856-860. [PubMed]","DOI":"10.1002\/ijc.1282"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Inaoka RJ, Jungbluth AA, Baiocchi OC, Assis MC, Hanson NC, Frosina D, Tassello J, Bortoluzzo AB, Alves AC and Colleoni GW. An overview of cancer\/testis antigens expression in classical Hodgkin\u2019s lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients. BMC Cancer. 2011; 11(1):416. [PubMed] https:\/\/doi.org\/10.1186\/1471-2407-11-416.","DOI":"10.1186\/1471-2407-11-416"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S, Amini RM, Botling J, Borresen-Dale AL, Sorlie T and Warnberg F. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol. 2010; 4(4):357-368. [PubMed] https:\/\/doi.org\/10.1016\/j.molonc.2010.06.007.","DOI":"10.1016\/j.molonc.2010.06.007"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ and Altorki NK. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005; 11(22):8055-8062. [PubMed]","DOI":"10.1158\/1078-0432.CCR-05-1203"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Tyagi P and Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer. 2009; 10(5):371374. [PubMed]","DOI":"10.3816\/CLC.2009.n.052"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, Spayne J, Taylor C and Paszat L. HER2\/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer. 2012; 106(6):1160-1165. [PubMed] https:\/\/doi.org\/10.1038\/bjc.2012.41.","DOI":"10.1038\/bjc.2012.41"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, Fox KR, Zhang PJ and Czerniecki BJ. HER-2\/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18(5):1386-1389. [PubMed] https:\/\/doi.org\/10.1158\/1055-9965.EPI-08-1101.","DOI":"10.1158\/1055-9965.EPI-08-1101"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Nofech-Mozes S, Spayne J, Rakovitch E, Kahn HJ, Seth A, Pignol JP, Lickley L, Paszat L and Hanna W. Biological Markers Predictive of Invasive Recurrence in DCIS. Clin Med Oncol. 2008; 2:7-18. [PubMed]","DOI":"10.1177\/117955490800200202"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Shekhar MP, Kato I, Nangia-Makker P and Tait L. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63\/Her2\/neu expressing subgroup. Oncotarget. 2013; 4(2):231-241. [PubMed] https:\/\/doi.org\/10.18632\/oncotarget.818.","DOI":"10.18632\/oncotarget.818"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Ademuyiwa FO, Bshara W, Attwood K, Morrison C, Edge SB, Ambrosone CB, O\u2019Connor TL, Levine EG, Miliotto A, Ritter E, Ritter G, Gnjatic S and Odunsi K. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS One. 2012; 7(6):e38783. [PubMed] https:\/\/doi.org\/10.1371\/journal.pone.0038783.","DOI":"10.1371\/journal.pone.0038783"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Siziopikou KP. Ductal carcinoma in situ of the breast: current concepts and future directions. Arch Pathol Lab Med. 2013; 137(4):462-466. [PubMed]","DOI":"10.5858\/arpa.2012-0078-RA"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Fracol M, Xu S, Mick R, Fitzpatrick E, Nisenbaum H, Roses R, Fisher C, Tchou J, Fox K, Zhang P and Czerniecki BJ. Response to HER-2 Pulsed DC1 Vaccines is Predicted by Both HER-2 and Estrogen Receptor Expression in DCIS. Ann Surg Oncol. 2013. [PubMed]","DOI":"10.1245\/s10434-013-3119-y"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, Gnjatic S, Williamson B, Scanlan MJ, Ono T, Sakita I, Yasui M, et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res. 2004; 64(6):2199-2204. [PubMed]","DOI":"10.1158\/0008-5472.CAN-03-3070"},{"key":"25","doi-asserted-by":"crossref","unstructured":"McElwee JL, Mohanan S, Griffith OL, Breuer HC, Anguish LJ, Cherrington BD, Palmer AM, Howe LR, Subramanian V, Causey CP, Thompson PR, Gray JW and Coonrod SA. Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer. 2012; 12:500. [PubMed] https:\/\/doi.org\/10.1186\/1471-2407-12-500.","DOI":"10.1186\/1471-2407-12-500"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Jang MH, Kim EJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Kim IA and Park SY. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res. 2012; 14(4):R115. [PubMed] https:\/\/doi.org\/10.1186\/bcr3239.","DOI":"10.1186\/bcr3239"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Lengerke C, Fehm T, Kurth R, Neubauer H, Scheble V, Muller F, Schneider F, Petersen K, Wallwiener D, Kanz L, Fend F, Perner S, Bareiss PM and Staebler A. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer. 2011; 11:42. [PubMed] https:\/\/doi.org\/10.1186\/1471-2407-11-42.","DOI":"10.1186\/1471-2407-11-42"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Knudsen ES, Dervishaj O, Kleer CG, Pajak T, Schwartz GF and Witkiewicz AK. EZH2 and ALDH1 expression in ductal carcinoma in situ: Complex association with recurrence and progression to invasive breast cancer. Cell Cycle. 2013; 12(13). [PubMed] https:\/\/doi.org\/10.4161\/cc.25065.","DOI":"10.4161\/cc.25065"}],"container-title":["Oncoscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncoscience.us\/lookup\/doi\/10.18632\/oncoscience.4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T18:43:04Z","timestamp":1594492984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncoscience.us\/lookup\/doi\/10.18632\/oncoscience.4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["4","25593980"],"URL":"https:\/\/doi.org\/10.18632\/oncoscience.4","relation":{},"ISSN":["2331-4737"],"issn-type":[{"value":"2331-4737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,12]]}}}